Table of Contents
- Introduction
- Taxonomy and Classification
- Morphology and Microscopy
- Cultural and Growth Characteristics
- Biochemical and Identification Tests
- Beneficial Colonization and Protective Role
- Virulence Factors (Beneficial Factors)
- Epidemiology
- Transmission
- Clinical Benefits
- Laboratory Diagnosis
- Treatment
- Prevention and Control
- Conclusion
- References
Introduction to Bifidobacterium bifidum
- Bifidobacterium bifidum is an important beneficial microorganism that naturally colonizes the human gastrointestinal tract, particularly during infancy.
- It is especially abundant in breastfed infants, where it contributes to the early development and establishment of a healthy and balanced gut microbiota.
- B. bifidum is naturally found in several body sites of healthy individuals, including the intestines, oral cavity, and vagina.
- The species is widely recognized for its probiotic properties and has been extensively investigated for its potential health-promoting effects.
- B. bifidum contributes to host health through several mechanisms, including:
- Supporting digestion and nutrient utilization.
- Fermenting complex carbohydrates and producing short-chain fatty acids (SCFAs).
- Inhibiting or limiting the growth and colonization of pathogenic microorganisms.
- Supporting the integrity and function of the intestinal barrier.
- Modulating and supporting appropriate immune system responses.
- Because of these beneficial properties, B. bifidum is commonly used in probiotic foods, functional foods, and dietary supplements intended to support gastrointestinal health and overall well-being.
- Its established history of use and documented health-promoting characteristics have made B. bifidum one of the widely studied probiotic bacteria in nutritional, microbiological, and medical research.
- Overall, B. bifidum is an important member of the human microbiota and a prominent probiotic species because of its association with gut microbiota development, intestinal health, microbial balance, and host–microbe interactions.
Taxonomy and Classification of Bifidobacterium bifidum
- Domain: Bacteria
- Phylum: Actinomycetota
- Class: Actinomycetes
- Order: Bifidobacteriales
- Family: Bifidobacteriaceae
- Genus: Bifidobacterium
- Species: Bifidobacterium bifidum (B. bifidum)
Note: The term “Kingdom: Bacilli” is not generally used as a standard taxonomic rank for B. bifidum. Bacilli is primarily recognized as a class within the phylum Bacillota, whereas Bifidobacterium belongs to the phylum Actinomycetota. Therefore, it is better to omit the “Kingdom: Bacilli” entry from your website taxonomy.
Morphology and Microscopy of Bifidobacterium bifidum
- Bifidobacterium bifidum is a Gram-positive, rod-shaped bacterium that typically appears singly or may occur in pairs, short chains, or clusters.
- The cells are approximately 0.5–1.3 µm in width and 1.5–8 µm in length.
- B. bifidum is non-motile, meaning it does not possess structures for active movement.
- It is non-spore-forming and does not produce endospores under normal conditions.
- The bacterium is pleomorphic, meaning its cellular morphology can vary considerably. Cells may appear branched, bifurcated, Y-shaped, V-shaped, club-shaped, curved, or irregular.
- Following Gram staining, the cells retain the crystal violet stain and therefore appear purple under the microscope.
- Microscopically, B. bifidum is characteristically observed as purple, irregular or branched rods, with distinctive Y-shaped and V-shaped forms being commonly associated with its bifid morphology.
- The characteristic branching and bifurcation of the cells contribute to the “bifid” appearance from which the species and genus derive their name.
Cultural and Growth Characteristics of Bifidobacterium bifidum
- Bifidobacterium bifidum is an obligate anaerobe, meaning it requires an oxygen-free environment for optimal growth.
- Optimum growth temperature: Approximately 37°C, corresponding closely to the temperature of the human body.
- Optimum pH: Approximately 6.5–7.0.
- B. bifidum grows well on selective and enrichment media commonly used for the cultivation of bifidobacteria, including de Man–Rogosa–Sharpe (MRS) agar, TPY agar, and Bifidobacterium Selective Medium (BSM).
Growth on Different Culture Media
- Nutrient Agar: Growth is generally poor or absent. When growth occurs, colonies are usually sparse and very small.
- MacConkey Agar: No growth is typically observed.
- Chocolate Agar: Produces small, smooth, convex, cream-colored colonies.
- Blood Agar: Forms small, smooth, circular, convex colonies that are grayish-white to cream-colored and non-hemolytic.
- Columbia Blood Agar: Colonies are typically smooth, convex, grayish-white to cream-colored, and non-hemolytic.
- MRS Agar supplemented with L-cysteine: Produces approximately 1–3 mm colonies that are small, circular, convex, smooth, creamy-white, opaque, and glistening. L-cysteine helps create a more suitable reduced environment for this anaerobic organism.
- TPY (Trypticase–Phytone–Yeast Extract) Agar: Produces round, smooth, convex, creamy-white colonies.
- Bifidobacterium Selective Medium (BSM): Typically produces cream-colored, smooth, convex, and opaque colonies.
Important: Colony morphology can vary depending on the strain, medium composition, incubation atmosphere, incubation time, and culture conditions. Therefore, colony appearance should be interpreted together with Gram staining, microscopic morphology, biochemical characteristics, and appropriate identification methods.
Biochemical and Identification Tests of Bifidobacterium bifidum
The biochemical profile of Bifidobacterium bifidum can be used to support its identification and differentiate it from other bacterial species. However, some carbohydrate fermentation reactions may vary among strains.
Biochemical and Identification Tests of Bifidobacterium bifidum
The biochemical profile of Bifidobacterium bifidum can support
its identification and help differentiate it from other bacterial species.
Some carbohydrate fermentation reactions may vary among individual strains.
Biochemical Test Results
| Test | Result |
|---|---|
| Catalase | Negative |
| Oxidase | Negative |
| Indole | Negative |
| OF (Oxidative-Fermentative) | Fermentative |
| 2% Bile Salt | Positive |
| Gelatin Hydrolysis | Negative |
| Nitrate Reduction | Negative |
| Gas Production | Negative |
Catalase
Result: Negative
Oxidase
Result: Negative
Indole
Result: Negative
OF (Oxidative-Fermentative)
Result: Fermentative
2% Bile Salt
Result: Positive
Gelatin Hydrolysis
Result: Negative
Nitrate Reduction
Result: Negative
Gas Production
Result: Negative
Carbohydrate Fermentation Profile
| Carbohydrate | Result |
|---|---|
| Amylose | Variable |
| Cellobiose | Negative |
| Fructose-6-phosphate | Positive |
| Galactose | Positive |
| Glucose | Positive |
| Inulin | Negative |
| Lactose | Positive |
| Maltase | Positive |
| Maltose | Variable |
| Mannitol | Negative |
| Mannose | Negative |
| Melibiose | Variable |
| Pectin | Negative |
| Raffinose | Negative |
| Ribose | Negative |
| Salicin | Negative |
| Sorbitol | Negative |
| Starch | Negative |
| Sucrose | Variable |
| Trehalose | Negative |
| Xylan | Negative |
| Xylose | Negative |
Amylose
Result: Variable
Cellobiose
Result: Negative
Fructose-6-phosphate
Result: Positive
Galactose
Result: Positive
Glucose
Result: Positive
Inulin
Result: Negative
Lactose
Result: Positive
Maltase
Result: Positive
Maltose
Result: Variable
Mannitol
Result: Negative
Mannose
Result: Negative
Melibiose
Result: Variable
Pectin
Result: Negative
Raffinose
Result: Negative
Ribose
Result: Negative
Salicin
Result: Negative
Sorbitol
Result: Negative
Starch
Result: Negative
Sucrose
Result: Variable
Trehalose
Result: Negative
Xylan
Result: Negative
Xylose
Result: Negative
Enzymatic Reactions
| Enzymatic Reaction | Result |
|---|---|
| Arabinosidases | Positive |
| Fructose-6-phosphoketolase | Positive |
| Glucosidases | Positive |
| Glutamate dehydrogenase | Positive |
| Glutamine synthetase | Positive |
| Hexosaminidases | Positive |
| ONPG (β-galactosidase) | Positive |
Arabinosidases
Result: Positive
Fructose-6-phosphoketolase
Result: Positive
Glucosidases
Result: Positive
Glutamate dehydrogenase
Result: Positive
Glutamine synthetase
Result: Positive
Hexosaminidases
Result: Positive
ONPG (β-galactosidase)
Result: Positive
Note: Biochemical and carbohydrate fermentation profiles
may vary between strains and according to culture conditions. These results
should therefore be interpreted together with microscopic morphology,
cultural characteristics, and appropriate identification methods.
Beneficial Colonization and Protective Role of Bifidobacterium bifidum
- Bifidobacterium bifidum is generally regarded as a beneficial commensal and probiotic bacterium rather than a pathogen. Consequently, it does not possess a conventional pathogenic mechanism under normal conditions.
- Instead, B. bifidum contributes to host health through multiple beneficial interactions within the gastrointestinal tract.
- Intestinal colonization: B. bifidum can colonize the intestinal mucosa, particularly during infancy. It attaches to intestinal epithelial cells through surface-associated structures and adhesion mechanisms, including adhesins.
- Carbohydrate fermentation: Following colonization, the bacterium metabolizes dietary carbohydrates and human milk oligosaccharides (HMOs), producing organic acids and other metabolites, including lactic acid and acetic acid.
- Reduction of intestinal pH: The production of organic acids contributes to a lower intestinal pH, creating conditions that can limit the growth and colonization of many potentially pathogenic microorganisms.
- Competition with harmful microorganisms: B. bifidum competes with potentially harmful microbes for available nutrients and attachment sites on the intestinal mucosa, thereby contributing to microbial balance.
- Production of antimicrobial substances: The bacterium can produce or contribute to the production of antimicrobial compounds and metabolites that may inhibit competing microorganisms.
- Strengthening of the intestinal barrier: B. bifidum can support intestinal epithelial barrier integrity, helping maintain the protective function of the gut lining.
- Mucus production: Its interactions with intestinal cells can promote or support mucus production, contributing to the protective mucosal layer of the gastrointestinal tract.
- Immune modulation: B. bifidum interacts with the host immune system and can influence both innate and adaptive immune responses, including the production of protective cytokines and the activity of regulatory immune cells.
- Maintenance of intestinal homeostasis: Through these combined activities, B. bifidum contributes to microbial equilibrium, intestinal homeostasis, and regulation of inflammatory responses.
- Protection against gastrointestinal infections: Its ability to compete with undesirable microorganisms, modify the intestinal environment, support the epithelial barrier, and modulate immunity may contribute to protection against certain gastrointestinal infections.
Opportunistic Infections
- Although B. bifidum has a long history of use as a probiotic and is generally considered safe, rare opportunistic infections have been reported.
- Such infections may include bacteremia or sepsis, particularly in individuals with significant underlying illnesses or severely compromised immune systems.
- Premature infants and other vulnerable patient populations may also be at increased risk of rare invasive infections.
- Therefore, while B. bifidum is predominantly associated with beneficial host–microbe interactions, its potential to cause opportunistic infection should be considered in severely vulnerable individuals.
Beneficial Factors of Bifidobacterium bifidum
Bifidobacterium bifidum is generally regarded as a beneficial probiotic and commensal bacterium of the human gastrointestinal tract rather than a major pathogen. Therefore, it does not possess the classical virulence factors typically associated with pathogenic bacteria. Instead, it has a range of adaptation, colonization, persistence, and host-interaction mechanisms that contribute to its probiotic functions.
1. Adhesion Factors
- B. bifidum possesses surface-associated proteins and lipoproteins that facilitate attachment to intestinal epithelial cells and the mucus layer.
- These adhesion mechanisms help the bacterium establish and maintain colonization within the gastrointestinal tract.
- Adhesion also allows B. bifidum to interact closely with host cells and the intestinal environment.
2. Pili
- Pili are hair-like surface structures that can contribute to bacterial attachment to the intestinal mucosa.
- They facilitate interactions between bacterial cells and host tissues or mucosal surfaces.
- Pili may also contribute to biofilm development and stable colonization.
3. Exopolysaccharides (EPS)
- Exopolysaccharides are extracellular polysaccharide materials associated with the bacterial cell surface.
- EPS can provide protection against environmental stresses, including acidic conditions and other gastrointestinal stresses.
- They can contribute to biofilm formation, surface adhesion, and persistence within the intestinal environment.
- EPS may also influence interactions between B. bifidum and the host immune system.
4. Mucin-Degrading Enzymes
- B. bifidum produces glycosidases and other carbohydrate-active enzymes that enable it to utilize carbohydrates derived from mucin.
- These enzymes allow the bacterium to access nutrients within the intestinal mucus layer.
- Mucin-associated carbohydrate utilization can support bacterial survival, growth, and persistence within the gastrointestinal tract.
5. Stress-Resistance Mechanisms
- B. bifidum possesses mechanisms that help it tolerate environmental stresses encountered during gastrointestinal transit.
- Acid- and bile-tolerance mechanisms assist survival during passage through the stomach and small intestine.
- These adaptations increase the likelihood of the bacterium reaching the intestine in a viable state and subsequently contributing to gut colonization.
6. Iron and Nutrient Acquisition Systems
- Like other microorganisms, B. bifidum requires essential nutrients and trace elements for growth and cellular functions.
- It possesses mechanisms for acquiring and utilizing nutrients available within the intestinal environment, including systems involved in obtaining iron and other essential micronutrients.
- These mechanisms support growth, survival, and persistence within the gastrointestinal tract.
7. Biofilm Formation
- B. bifidum can participate in biofilm formation on mucosal and other surfaces.
- Biofilm-associated growth can improve bacterial persistence and provide protection from environmental stresses.
- Biofilm formation may therefore contribute to the organism's ability to establish longer-term colonization within the gastrointestinal environment.
Key Point The term “beneficial factors” is more appropriate than “virulence factors” when describing these characteristics of B. bifidum. These mechanisms primarily support adhesion, survival, nutrient utilization, host interaction, biofilm formation, and intestinal persistence, rather than causing disease.
Epidemiology of Bifidobacterium bifidum
- Unlike pathogenic bacteria, Bifidobacterium bifidum is primarily a commensal and probiotic microorganism. Therefore, its epidemiology focuses mainly on its distribution, prevalence, abundance, colonization, and ecological role rather than disease incidence.
- B. bifidum is an important member of the human intestinal microbiota, particularly during early life. Bifidobacteria can be abundant in the gut of healthy infants and remain part of the intestinal microbial community throughout childhood and adulthood, although their abundance and species composition can change with age.
- Colonization and abundance of B. bifidum can vary according to several factors, including:
- Age
- Diet and feeding practices
- Health status
- Geographic location
- Antibiotic exposure
- Composition of the surrounding gut microbiota
- Dietary sources: Bifidobacteria may be present in certain fermented foods, dairy products, and probiotic products. However, the presence and abundance of B. bifidum specifically can vary considerably among individual products.
- Antibiotic exposure: Antibiotic treatment can disrupt the normal intestinal microbiota and may reduce the abundance of bifidobacteria, including B. bifidum.
- Disease and altered gut microbiota: Changes in intestinal microbial communities have been reported in conditions such as inflammatory bowel disease (IBD). However, the abundance of B. bifidum can vary among patients and disease states, so it should not be assumed that its reduction occurs uniformly in every individual.
Transmission and Acquisition of Bifidobacterium bifidum
Because B. bifidum is primarily a commensal/probiotic organism rather than a pathogen, the term acquisition or colonization is generally more appropriate than pathogen-style transmission.
1. Vertical Acquisition: Mother-to-Infant
- Early-life acquisition of bifidobacteria can occur through maternal and environmental microbial exposure during and after birth.
- During vaginal delivery, newborns are exposed to microorganisms originating from the maternal vaginal and intestinal microbiota, which can contribute to early microbial colonization.
- Breast milk is another important source of microbial exposure and contains microorganisms as well as human milk components that selectively support the growth of certain bifidobacteria.
- Human milk oligosaccharides (HMOs) are particularly important because they serve as selective substrates for bifidobacteria, helping shape the infant gut microbiota.
2. Horizontal Acquisition
- Bifidobacteria may also be acquired from the surrounding human and environmental microbiota.
- Potential sources include close interactions with family members, caregivers, and other individuals.
- Microbial transfer can occur through ordinary environmental contact, although the relative contribution of these routes to B. bifidum colonization is not always clearly established.
3. Environmental and Dietary Acquisition
- Infants and adults are continuously exposed to microorganisms from their surrounding environment, including household surfaces, objects, food, and water.
- Dietary exposure may occur through fermented foods and probiotic products containing bifidobacteria.
- Examples of foods that may contain bifidobacteria or other beneficial lactic-acid bacteria include yogurt and kefir. However, not every fermented food contains B. bifidum, and the specific species and viable counts depend on the product and manufacturing process.
Key Point The epidemiology of B. bifidum is best understood in terms of early-life colonization, persistence within the gastrointestinal microbiota, dietary and environmental exposure, and factors that influence its abundance. Unlike pathogens, its presence generally represents part of the normal host-associated microbial community rather than an indicator of infection.
Clinical Benefits of Bifidobacterium bifidum
Bifidobacterium bifidum is a commonly studied probiotic species associated with several potential gastrointestinal and immune-related benefits. However, effects can be strain-specific, and clinical evidence varies depending on the condition, probiotic preparation, dose, and patient population.
1. Digestive Health
- B. bifidum contributes to the metabolism of complex carbohydrates and dietary substrates in the intestine.
- Its fermentation activities produce metabolites such as acetate and other short-chain fatty acids (SCFAs) that can support intestinal microbial and epithelial health.
- By contributing to a balanced gut microbiota, it may indirectly support normal digestive function.
2. Intestinal Microbial Balance
- B. bifidum can contribute to the maintenance of a balanced intestinal microbial community.
- It may compete with potentially harmful microorganisms for nutrients and attachment sites.
- Its metabolic products and interactions with other members of the microbiota can create conditions that are less favorable for some undesirable microorganisms.
3. Diarrhea Prevention and Management
- Certain probiotic preparations containing Bifidobacterium species may help reduce the risk or duration of some forms of diarrhea, including antibiotic-associated or infectious diarrhea.
- Probiotic effects are strain- and formulation-dependent, so evidence for B. bifidum specifically should not be generalized to all diarrhea cases.
- Probiotics may also help support the restoration of the intestinal microbial community following antibiotic-associated disruption.
4. Potential Role in Irritable Bowel Syndrome (IBS)
- Some probiotic preparations containing bifidobacteria have been investigated for their potential to improve IBS-associated symptoms.
- Reported outcomes include possible reductions in abdominal discomfort, bloating, flatulence, and altered bowel habits.
- Clinical responses vary considerably among individuals and probiotic strains.
5. Immune Modulation
- B. bifidum interacts with the intestinal mucosal immune system and may influence both innate and adaptive immune responses.
- It can affect the production of immune-regulatory cytokines and other signaling molecules.
- Some studies suggest that bifidobacteria can influence mucosal immune defenses, including IgA-associated responses, although effects depend on the strain and host.
6. Support of Intestinal Barrier Function
- B. bifidum may contribute to the maintenance of intestinal epithelial integrity.
- Its interactions with intestinal cells and microbial metabolites can influence tight-junction function and intestinal permeability.
- Supporting the epithelial barrier may help limit the passage of potentially harmful microbial products across the intestinal lining.
7. Modulation of Inflammation
- B. bifidum can interact with immune cells and influence the production of pro-inflammatory and regulatory cytokines.
- These interactions may contribute to immune homeostasis and help regulate excessive intestinal inflammatory responses.
- The magnitude and clinical relevance of these effects vary among strains and clinical conditions.
8. Potential Benefits During Infancy
- B. bifidum is an important member of the microbiota of many healthy infants, particularly during early life.
- It can utilize human milk oligosaccharides (HMOs) and other complex carbohydrates available in the infant intestinal environment.
- Through interactions with the developing gut microbiota and immune system, bifidobacteria may contribute to intestinal and immune development.
- Certain probiotic preparations have been studied for their potential role in reducing some gastrointestinal infections in infants, although benefits depend on the specific strain and clinical setting.
9. Potential Role in Allergic Disease
- Bifidobacteria can influence the development and regulation of mucosal immune responses, which has led to investigation of their possible role in allergic diseases.
- Some probiotic interventions have reported effects on conditions such as atopic dermatitis, but results across studies are inconsistent.
- Evidence is not sufficient to consider B. bifidum alone a proven treatment or preventive measure for food allergy or other allergic diseases.
10. Potential Metabolic Effects
- Research is investigating whether B. bifidum and other probiotic bacteria can influence aspects of glucose metabolism, lipid metabolism, energy balance, and body weight.
- These effects may involve interactions between the gut microbiota, intestinal barrier, microbial metabolites, and host metabolism.
- However, clinical evidence remains variable, and B. bifidum should not be considered an established treatment for metabolic disorders.
11. Potential Role in Inflammatory Bowel Disease (IBD)
- Bifidobacteria have been investigated as part of microbiome-based approaches for gastrointestinal inflammatory disorders, including ulcerative colitis and Crohn's disease.
- Potential mechanisms include modulation of the intestinal microbiota, support of epithelial barrier function, and regulation of inflammatory responses.
- Evidence for probiotics in IBD is condition- and formulation-specific, and B. bifidum should not be presented as a standalone treatment for ulcerative colitis or Crohn's disease.
Rare Opportunistic Infections
Although B. bifidum is generally considered a beneficial microorganism, rare invasive infections have been reported, particularly in patients with severe underlying disease, compromised immunity, prematurity, or other major risk factors. These cases are uncommon and should not be interpreted as typical effects of probiotic use.
Potentially reported clinical presentations include:
| Condition | Possible Clinical Features |
|---|---|
| Bacteremia | Fever, chills, malaise, and, in severe cases, hypotension. |
| Sepsis | Temperature abnormalities, tachycardia, tachypnea, hypotension, and organ dysfunction. |
| Infective Endocarditis | Persistent fever, cardiac murmur, fatigue, weakness, weight loss, and possible embolic complications. |
| Intra-abdominal Infection | Abdominal pain or tenderness, fever, peritonitis, and possible intra-abdominal abscess formation. |
| Neonatal Infection | Feeding intolerance, lethargy, respiratory distress, temperature instability, and signs of neonatal sepsis. |
| Wound and Soft-Tissue Infection | Localized pain, redness, swelling, purulent discharge, and delayed wound healing. |
| Urinary Tract Infection | Dysuria, increased urinary frequency, urgency, and suprapubic discomfort. |
Important Clinical Note
The beneficial effects of B. bifidum are strain-specific and cannot automatically be generalized from one probiotic product or clinical trial to all B. bifidum strains. Similarly, the rare invasive infections described above occur mainly in vulnerable individuals and are distinct from the organism's usual role as a commensal/probiotic member of the gut microbiota.
Laboratory Diagnosis of Bifidobacterium bifidum
Laboratory identification of Bifidobacterium bifidum involves a combination of sample collection, microscopic examination, anaerobic culture, biochemical characterization, and molecular methods. Because phenotypic characteristics may vary among strains, molecular techniques are often used for confirmation.
1. Sample Collection
The type of sample depends on the purpose of the investigation:
- Fecal samples: Most suitable for studies of intestinal colonization, gut microbiota analysis, and detection of B. bifidum in the gastrointestinal tract.
- Food and probiotic samples: Useful for detecting B. bifidum in fermented dairy products, probiotic formulations, and dietary supplements.
- Samples should be collected and transported under conditions that preserve the viability of anaerobic bacteria.
2. Microscopic Examination
- A Gram stain is performed on suspected colonies.
- B. bifidum appears as Gram-positive (purple-colored), pleomorphic rods.
- Cells commonly show Y-shaped, V-shaped, branched, curved, or club-shaped morphologies under the microscope.
- These characteristic branching forms provide an initial indication of the presence of bifidobacteria.
3. Culture Characteristics
- B. bifidum is an obligate anaerobe and requires oxygen-free conditions for optimal growth.
- Growth is generally poor or absent on Nutrient Agar and MacConkey Agar.
- On Chocolate Agar, colonies are usually small, smooth, convex, and cream-colored.
- On Blood Agar and Columbia Blood Agar, colonies are typically small, smooth, circular, convex, grayish-white to cream-colored, and non-hemolytic.
- MRS Agar supplemented with L-cysteine is commonly used for cultivation and produces small (1–3 mm), circular, smooth, creamy-white, opaque, and glistening colonies.
- On TPY (Trypticase–Phytone–Yeast Extract) Agar, colonies are generally round, smooth, convex, and creamy-white.
- Bifidobacterium Selective Medium (BSM) supports selective growth and usually produces cream-colored, smooth, convex, and opaque colonies.
4. Biochemical Identification
After isolation, colonies can be subjected to biochemical testing. A typical profile of B. bifidum includes:
- Catalase: Negative
- Oxidase: Negative
- Indole: Negative
- Oxidative-Fermentative (OF) Test: Fermentative
- 2% Bile Salt Tolerance: Positive
- Gelatin Hydrolysis: Negative
- Nitrate Reduction: Negative
- Gas Production: Negative
These biochemical characteristics should be interpreted alongside cultural and microscopic findings because some reactions may vary among strains.
5. Molecular Methods
- PCR (Polymerase Chain Reaction)
- PCR uses species-specific primers for the detection of B. bifidum.
- The 16S rRNA gene is commonly targeted for identification.
Interactive PCR Cycle
Explore the three major steps of PCR amplification.
DNA Denaturation
95°C
Heat separates the double-stranded DNA template into two single strands.
Step 1 of 3
Real-Time PCR (qPCR)
- Real-time PCR allows rapid and quantitative detection of B. bifidum.
- It is useful for measuring bacterial abundance in fecal samples, food products, and probiotic preparations.
16S rRNA Gene Sequencing
- 16S rRNA sequencing provides accurate bacterial identification and phylogenetic analysis.
- It helps differentiate B. bifidum from many other bacterial species.
- For precise strain-level identification, additional molecular markers or genomic methods may be required.
Treatment of Bifidobacterium bifidum
Bifidobacterium bifidum is not considered a primary pathogenic bacterium. It is a normal member of the intestinal microbiota and is also used as a probiotic. Therefore, normal intestinal colonization does not require antimicrobial treatment. Selected B. bifidum-containing probiotic preparations may be used for various gastrointestinal and microbiota-related purposes, although their effects are strain-, formulation-, dose-, and condition-dependent.
- Diarrhea: Some probiotic preparations containing Bifidobacterium may help prevent or reduce certain types of diarrhea, including antibiotic-associated diarrhea.
- Irritable bowel syndrome (IBS): Certain Bifidobacterium-containing probiotics have been studied for improving symptoms such as abdominal discomfort, bloating, and altered bowel habits, although results vary.
- Post-antibiotic microbiota support: Probiotic preparations may be used to support the recovery and maintenance of the intestinal microbiota following antibiotic therapy.
- Immune modulation: B. bifidum can interact with the intestinal immune system and has been investigated for potential immunomodulatory effects; benefits for allergic conditions remain strain- and condition-specific.
- Infant gut health: B. bifidum is an important early-life intestinal microorganism and has been investigated in probiotic preparations intended to support infant gastrointestinal health.
- Opportunistic infections: Rare invasive infections, such as bacteremia or sepsis, have been reported, particularly in premature infants, severely immunocompromised individuals, or patients with serious underlying conditions. In such cases, treatment is based on the clinical condition and microbiological evidence.
- Supportive treatment: Severe infections may require hospitalization, intravenous fluids, oxygen therapy, and hemodynamic support when clinically indicated.
- Antimicrobial therapy: Antibiotics may be required for clinically significant invasive infection. Selection should be guided by antimicrobial susceptibility testing (AST), infection site, patient-specific factors, and applicable clinical guidelines rather than using a fixed antibiotic regimen. β-lactam antibiotics and other agents may be considered when the isolate is susceptible.
- Important consideration: Detection of B. bifidum from the gastrointestinal tract or another non-sterile site does not by itself establish infection. Antimicrobial treatment is generally reserved for cases with compatible clinical findings and evidence of clinically significant or invasive infection.
Prevention and Control of Bifidobacterium bifidum
Because Bifidobacterium bifidum is generally a beneficial commensal and probiotic organism, prevention and control do not aim to eliminate it from the body. Instead, they focus on maintaining a healthy gut microbiota and reducing the risk of rare opportunistic infections, particularly in vulnerable individuals.
- Maintenance of Normal Gut Microbiota: Consume a balanced, fiber-rich diet to support beneficial intestinal microorganisms. Breastfeeding in infants can promote the development of a healthy gut microbiota. Probiotics may be considered when clinically appropriate, particularly when supported by evidence for the specific strain and condition. Avoid unnecessary practices that can disrupt the normal gut microbiota.
- Proper Use of Antibiotics: Antibiotics should be used only when clinically indicated and according to appropriate medical guidance. Avoiding unnecessary or inappropriate antibiotic use helps minimize disruption of the normal gut microbiota and may reduce microbiota-associated complications, particularly in vulnerable individuals.
- Prevention in High-Risk Individuals: Patients who are severely immunocompromised, premature infants, and individuals with serious underlying conditions should be monitored carefully for signs of invasive infection. Unnecessary invasive devices, such as urinary catheters and vascular devices, should be avoided when possible and removed promptly when no longer required. Appropriate infection-prevention practices should be followed during their use.
- Safe Use of Probiotics: Use quality-controlled probiotic products from reliable sources and follow recommended storage and handling conditions. Probiotic use in severely immunocompromised patients or other high-risk individuals should be discussed with a healthcare professional because, although uncommon, invasive infections associated with probiotic organisms have been reported.
- Neonatal and Maternal Care: Breastfeeding should be supported when appropriate because it contributes to the development of the infant gut microbiota. Proper hygiene and infection-prevention practices should be maintained during delivery and neonatal care. Antibiotics in mothers and neonates should be used only when clinically indicated and according to appropriate medical guidance.
Conclusion
- Bifidobacterium bifidum is a Gram-positive, anaerobic bacterium that forms an important part of the normal human gut microbiota, particularly during early infancy.
- It is widely recognized as a beneficial commensal and probiotic microorganism that contributes to intestinal microbial balance, carbohydrate fermentation, gut barrier integrity, and modulation of immune responses.
- Its abundance is particularly notable in breastfed infants, where it contributes to the development of the early-life gut microbiota and may help limit the growth of certain pathogens.
- Although generally non-pathogenic, B. bifidum can rarely cause opportunistic infections, particularly in premature infants and severely immunocompromised individuals.
- Overall, B. bifidum is an important member of the human microbiota and a widely studied probiotic organism with potential applications in supporting gastrointestinal health and maintaining microbial balance.
References
- Aryal, S. (2022, March 8). Biochemical test of Bifidobacterium bifidum. Microbe Notes.
- Dosan, R., Mudana, S. O., Julyanto, C. M. P., Purnama, E. T., Sugata, M., Jo, J., & Tan, T. J. (2024). Isolation and identification of Bifidobacterium species from human breast milk and infant feces in Indonesia. Biodiversitas, 25(1), 337–343. https://doi.org/10.13057/biodiv/d250139
- Hilliard, M. A., & Sela, D. A. (2024). Transmission and persistence of infant gut-associated bifidobacteria. Microorganisms, 12(5), 879. https://doi.org/10.3390/microorganisms12050879
- Kouritzin, T. (n.d.). Bifidobacterium bifidum: Benefits, side effects and more. AllMax Nutrition.
- McIntyre, C., & Johnston, B. (2026, March 25). Bifidobacterium bifidum: Uses, side effects, interactions, pictures, warnings & dosing. WebMD.
- Mishra, M., Paliwal, J. S., Singh, S. K., & Abraham, J. (2012). Isolation and characterization of Bifidobacterium from fermented milk products and their antimicrobial studies. https://doi.org/10.13140/RG.2.2.20812.67208
- Rupa Health. (n.d.). Bifidobacterium bifidum. Rupa Health. https://www.rupahealth.com/biomarkers/bifidobacterium-bifidum
- Tannock, G. W. (1999). Identification of lactobacilli and bifidobacteria. Current Issues in Molecular Biology, 1(1), 53–64. https://doi.org/10.21775/cimb.001.053
- Turroni, F., Duranti, S., Milani, C., Lugli, G. A., van Sinderen, D., & Ventura, M. (2019). Bifidobacterium bifidum: A key member of the early human gut microbiota. Microorganisms, 7(11), 544. https://doi.org/10.3390/microorganisms7110544
